Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBV1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. The delivery order, issued on January 6, 2026, with an ultimate completion date of January 28, 2026, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion vehicle established on November 13, 2025, that positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations.
DMS Pharmaceutical Group supplies a comprehensive range of pharmaceutical products and medical consumables to federal military healthcare facilities worldwide, including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and over-the-counter drugs. The PPV-G GEN V contract structure, part of DLA's broader $30.3 billion pharmaceutical acquisition strategy, authorizes the issuance of firm fixed-price delivery orders across multiple therapeutic categories to support recurring medical supply needs of the military medical system. The company's established performance on numerous prior delivery orders and its status as a woman-owned small business have enabled it to serve as a dependable supplier within the federal pharmaceutical supply chain since its registration in the System for Award Management in July 2001.
Quick answers
Who was awarded contract SPE2DR26FFBV1?
SPE2DR26FFBV1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FFBV1 worth?
The government has obligated $10,485 on SPE2DR26FFBV1.
Is contract SPE2DR26FFBV1 an order under another contract?
Yes. SPE2DR26FFBV1 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBV1 competed?
The extent of competition for SPE2DR26FFBV1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award